

IP 3 – HOW WILL PATIENT CENTRICITY BE CAPTURED IN THE JAPANESE HTA AND HEALTHCARE REFORM?

Moderator: Adrian Towse,
Director, Office of Health Economics
Visiting Professor, London School of Economics
www.ohe.org; atowse@ohe.org



Office of
Health
Economics
Research

Panellists and topics



- Professor Shunya Ikeda MD, International University of Health and Welfare, Narita City
 - View from the Japanese Academic Side
- Makoto Kobayashi PhD, Director and CEO, CRECON Medical Assessment, Tokyo
 - View from the Industry
- Durhane Wong-Rieger PhD, President and CEO, Canadian Organization for Rare Disorders
 - Patient Perspective on Patient Centricity in Healthcare Decision Making (including HTA)



Office of
Health
Economics
Research

Questions



- In what way is the patient involved and engaged in decision making overseas? What are the benefits, especially in terms of understanding value, broader decision frameworks and access to new medicines?
- How does this compare to the current patient engagement and practices in Japan?
- What challenges would need to be overcome in Japan to better involve the patient voice in the emerging Japanese HTA reforms? How?
- What type of collaborative approaches and evidence generation platforms could be conducive for better patient data capture? Who is, or should be engaged in these activities?
- What are the benefits for Japanese HTA to embed patient centricity and how can this be accomplished?
- What training and support can Japanese HTA offer to patient groups to ensure informed patient engagement?